BERNS Kristofer Dzhon (AU),БЁРНС Кристофер Джон (AU),DONOKh'Ju Andrju Krehjg (AU),ДОНОХЬЮ Андрю Крэйг (AU),FEUTRILL Dzhon Tomas (AU),ФЕУТРИЛЛ Джон Томас (AU),NGUJEN Tkhao Lien Tkhi (AU),НГУЙЕН Тхао Ли,BERNS KRISTOFER DZHON,БЁРНС Кристофер Джон,DONOKHJU ANDRJU KREHJG,ДОНОХЬЮ Андрю Крэйг,FEUTRILL DZHON TOMAS,ФЕУТРИЛЛ Джон Томас,NGUJEN TKHAO LIEN TKHI,НГУЙЕН Тхао Лиен Тхи,VILKS ANDRJU FREDERIK,ВИЛКС А
申请号：
RU2009137363/04
公开号：
RU0002498983C2
申请日:
2008.03.12
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
FIELD: chemistry.SUBSTANCE: invention relates to novel phenylaminopyrimidine compounds of formula I, which are JAK kinase inhibitors. In particular, these compounds selectively act on JAK2 kinase. The compounds can be used to treat diseases such as immunological and inflammatory diseases； hyperproliferative diseases, myeloproliferative diseases； viral diseases； metabolic diseases； and vascular diseases. In the compound of formula I , Q and Z are independently selected from N and CR1； R1 is independently selected from hydrogen, halogen, R2, OR2, OH, R4, OR4, CN, CF3, (CH2)nN(R2)2, where n equals 1,2 or 3, NO2, R2R4, NR2SO2R3, COR4, NR2COR3, CO2H, CO2R2, NR2COR4, R2CN, R2OH, R2OR3 and OR5R4； or two substitutes R1 together with carbon atoms with which they are bonded form an unsaturated 5- or 6-member heterocyclic ring containing 1-4 N atoms； R2 is C1-4alkyl； R4 is R2, C2-4alkenyl or phenyl； R4 is NH2, NHR2, N(R1)2, substituted or unsubstituted morpholine, CH2morpholine, substituted or unsubstituted thiomorpholine, substituted or unsubstituted thiomorpholino-1-oxide, substituted or unsubstituted thiomorpholino-1,1-dioxide, substituted or unsubstituted piperazinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted imidazolyl, substituted or tetrahydrofuranyl unsubstituted and substituted or unsubstituted tetrahydropyranyl； R5 is C2-4alkylene； R6-R9 are independently selected from H, RXCN, halogen, substituted or unsubstituted C1-4alkyl, OR1, CO2R1, N(R1)2, NO2 and CON(R1)2, wherein at least one of R6-R9 is RXCN； the rest of the values of the radicals are given in the claim.EFFECT: high efficiency of treatment.29 cl, 7 dwg, 2 tbl, 93 exНастоящее изобретение относится к новым соединениям фениламинопиримидина формулы I, которые являются ингибиторами JAK-киназ. В частности, эти соединения изби
